CORDA Investment Management LLC. Acquires 59,047 Shares of Pfizer Inc. (NYSE:PFE)

CORDA Investment Management LLC. grew its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 5.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,075,063 shares of the biopharmaceutical company's stock after acquiring an additional 59,047 shares during the quarter. Pfizer accounts for approximately 2.2% of CORDA Investment Management LLC.'s holdings, making the stock its 24th biggest holding. CORDA Investment Management LLC.'s holdings in Pfizer were worth $27,242,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in PFE. Clarity Asset Management Inc. bought a new stake in Pfizer in the fourth quarter valued at $27,000. Gould Capital LLC boosted its holdings in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares in the last quarter. North Capital Inc. bought a new stake in Pfizer in the first quarter valued at $28,000. Bernard Wealth Management Corp. bought a new stake in Pfizer in the fourth quarter valued at $30,000. Finally, Curio Wealth LLC bought a new stake in Pfizer in the fourth quarter valued at $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of NYSE PFE traded down $0.13 during midday trading on Friday, hitting $25.65. 34,836,956 shares of the company's stock traded hands, compared to its average volume of 41,815,652. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The stock has a market capitalization of $145.83 billion, a price-to-earnings ratio of 18.59, a price-to-earnings-growth ratio of 0.93 and a beta of 0.58. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The firm has a fifty day moving average of $23.86 and a 200 day moving average of $24.81.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm's revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.82 EPS. On average, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.71%. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Analyst Ratings Changes

PFE has been the topic of several recent analyst reports. The Goldman Sachs Group lifted their price target on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. TD Cowen dropped their target price on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a report on Tuesday, April 22nd. HSBC dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Jefferies Financial Group boosted their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. Finally, Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, Pfizer has a consensus rating of "Hold" and a consensus target price of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.